The aim is to track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index (index). The index is based on the MSCI ACWI IMI Index (Parent Index) and is designed to reflect the performance of the shares of large, medium, and small-capitalisation companies globally that derive, or are expected to derive, significant revenues from technological innovation in the genomic healthcare sector.